Stein Steven H

Stein Steven H serves as the Chief Medical Officer and Head of Late-Stage Development at Incyte Corporation, a biopharmaceutical company focused on innovative cancer therapies. His recent trading activity, tracked through SEC Form 4 filings, highlights a pattern of sale activity with reported amounts ranging from $254.4K to $1.6M between January 2025 and July 2026. Notably, his largest disclosed move involved a grant/exercise valued at approximately $2.1 million on January 21, 2026, underscoring his active role in the company's financial landscape.